Chronic stress is epidemic, and it is killing us. We know that and strive to become healthier. For some people that can be ...

Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

Examples of neurotransmitters include serotonin, dopamine, and norepinephrine. There are several types of antidepressants on the market. They all work slightly differently by targeting certain ...

It is most important to maintain a healthy and fit diet. Health experts say that we need nutrients through regular diet.

The creation of a “Make America Healthy Again Commission” has raised concerns over Washington youths' access to medications ...

with variants in the serotonin system being implicated in depression and impulsive-aggressive behaviours. Recent reports of rare large chromosomal deletions in autism and schizophrenia suggest ...

Genetics constitute a crucial risk factor to schizophrenia. In the last decade, molecular genetic research has produced novel findings, infusing optimism about discovering the biological roots of ...

OPC-4392 was shown to be effective against negative symptoms and showed no propensity to induce extrapyramidal symptoms in individuals with schizophrenia ... as at novel serotonin receptor ...

Brodmann area 22, namely the superior temporal gyrus, had a greater number of abnormally expressed genes in both diseases; moreover, genes that differentiated AD and schizophrenia patients from ...

Caplyta is a prescription drug used to treat schizophrenia and bipolar disorder. Learn how long it takes the drug to work and how long it stays in your system.

Background: Partial dopamine D 2 receptor agonists are used for psychotic symptoms in adults with schizophrenia spectrum disorders. Recently, interest surged for partial dopamine D 2 receptor agonists ...